MYBPC3
MYBPC3 encodes the cardiac myosin-binding protein C, which acts as a structural and regulatory component of the heart muscle sarcomere. It is the most common gene implicated in hypertrophic cardiomyopathy, where mutations often lead to heart wall thickening and impaired relaxation.
Key Takeaways
- •MYBPC3 is the most common gene responsible for genetic heart wall thickening.
- •It acts as a molecular "brake" to ensure the heart muscle can relax and fill with blood.
- •Most mutations lead to a reduction in protein levels, causing the heart to work too hard.
- •New precision medications can now directly target the hyper-contractile state caused by these mutations.
Basic Information
- Gene Symbol
- MYBPC3
- Full Name
- Myosin Binding Protein C3
- Also Known As
- cMyBP-CFHC
- Location
- 11p11.2
- Protein Type
- Structural Sarcomere Protein
- Protein Family
- Myosin-binding protein family
Related Isoforms
Key SNPs
A major pathogenic variant in familial hypertrophic cardiomyopathy.
Well-documented in clinical registries for its association with heart wall thickening.
A common structural variation prevalent in South Asian populations that increases the risk of progressive heart failure.
A regulatory variant that influences the expression levels of the MYBPC3 protein.
One of many nonsense mutations that lead to protein haploinsufficiency and severe cardiac phenotypes.
Overview
MYBPC3 (Myosin Binding Protein C3, cardiac-type) is a critical component of the cardiac sarcomere, which is the basic unit of heart muscle contraction. It acts as a molecular "brake" or regulator that fine-tunes the interaction between the thick and thin filaments of the heart muscle. Mutations in this gene are the single most common cause of hypertrophic cardiomyopathy (HCM). This condition is characterized by an abnormal thickening of the heart muscle, which can obstruct blood flow and lead to heart failure or dangerous heart rhythms.
The MYBPC3 gene provides instructions for making the cardiac myosin-binding protein C (cMyBP-C). This protein is a vital component of the sarcomere, which is the structure within heart muscle cells responsible for contraction and relaxation. It acts as a regulatory node that controls how the muscle fibers slide past each other during a heartbeat.
Research has established MYBPC3 as the most common gene implicated in hypertrophic cardiomyopathy (HCM). Unlike many other heart conditions that are caused by "wear and tear," HCM is a primary genetic disease of the heart muscle’s building blocks. Most people with an MYBPC3 mutation have a reduction in the amount of this protein, which leads to a heart that is hyper-contractile and metabolically inefficient.
Conceptual Model
A simplified mental model for the pathway:
Intentionally simplified; the disease is caused by the loss of the brake, not just the presence of a "bad" protein.
Core Health Impacts
- • Structural integrity: Primary determinant of heart muscle structural integrity.
- • Diastolic regulation: Regulates the relaxation phase (diastole) of the heartbeat.
- • Energy conservation: Prevents excessive energy consumption by "parking" myosin heads.
- • Hypertrophy defense: Protects against the development of pathological cardiac hypertrophy.
- • Fibrosis inhibition: Inhibits the signaling pathways that lead to heart muscle scarring.
- • Flow efficiency: Maintains efficient blood flow out of the heart’s main chamber.
Protein Domains
C0-C2 Domains
The N-terminal region that interacts with the thin filament (actin) and regulates the force of contraction.
M-Domain
The regulatory "hub" where phosphorylation by PKA and other kinases occurs to speed up heart relaxation.
C10 Domain
The C-terminal end that anchors the protein to the thick filament (myosin) and ensures proper alignment.
Upstream Regulators
KLF15 Activator
A key transcriptional regulator that coordinates the expression of cardiac structural proteins.
GATA5 Activator
A cardiac-specific transcription factor essential for the development and maintenance of the healthy sarcomere.
PKA Activator
Activated by epinephrine to phosphorylate cMyBP-C, which enhances the rate of heart muscle relaxation.
Thyroid Hormone (T3) Modulator
Regulates the transcription of myosin heavy chain isoforms and protein phosphorylation.
MEIS1 Activator
Involved in the developmental programs that establish cardiomyocyte architecture.
HAND2 Activator
A transcription factor that supports the expansion and maturation of ventricular muscle cells.
Downstream Targets
Cardiac Myosin Inhibits
The primary target; cMyBP-C regulates the "super-relaxed state" of myosin heads.
Actin Activates
Interaction with the thin filament helps stabilize the sarcomere and tune calcium sensitivity.
Titin Activates
Giant structural protein that works with cMyBP-C to maintain myofibril alignment.
NF-κB Signaling Inhibits
Activated when cMyBP-C levels are low, leading to inflammation and fibrosis.
TGF-β1 Inhibits
A pro-fibrotic cytokine that is upregulated in response to the mechanical stress of HCM.
Troponin Complex Activates
Regulatory proteins on the thin filament that coordinate with cMyBP-C to control contraction.
Role in Aging
The heart muscle naturally stiffens with age, a process known as diastolic aging. MYBPC3 is the primary protein that protects against the acceleration of this stiffening.
Proteostasis Decline
As we age, the quality control systems that maintain sarcomere proteins can falter, leading to a gradual loss of functional cMyBP-C.
Fibrotic Buildup
Chronic stress on the sarcomere due to MYBPC3 variants leads to the progressive replacement of muscle with scar tissue over many decades.
Adrenergic Blunting
The ability of the heart to speed up relaxation via cMyBP-C phosphorylation often declines with age, reducing exercise capacity.
Metabolic Strain
An inefficient sarcomere consumes more ATP; over a lifetime, this metabolic strain can contribute to the "failing" heart phenotype of old age.
Vascular Coupling
A stiff heart (driven by sarcomere dysfunction) coupled with stiff aging arteries leads to a rapid decline in cardiac output.
Late-Onset Hypertrophy
Many MYBPC3 variants have "incomplete penetrance," meaning the thickening only becomes clinically apparent in the 50s, 60s, or 70s.
Disorders & Diseases
Hypertrophic Cardiomyopathy (HCM)
The signature disorder of MYBPC3. It involves the thickening of the left ventricle, which can obstruct blood flow to the rest of the body.
Dilated Cardiomyopathy (DCM)
In some cases, MYBPC3 mutations lead to the heart chambers becoming enlarged and weakened rather than thickened.
Restrictive Cardiomyopathy
A rare condition where the heart walls are extremely rigid, making it nearly impossible for the heart to fill with blood.
LV Non-Compaction
A developmental disorder where the heart muscle has a "spongy" appearance, often seen alongside other MYBPC3 defects.
Heart Failure (HFpEF)
A common endgame for sarcomere diseases, where the heart can still pump but is too stiff to handle the body’s needs.
Interventions
Supplements
Essential for healthy muscle relaxation and may help support the diastolic function of the heart.
Supports mitochondrial energy production in heart cells under metabolic stress from hyper-contractility.
May help reduce systemic inflammation and support the overall electrical stability of the heart.
Deficiency is common in cardiomyopathy and may correlate with the severity of heart wall thickening.
Involved in fatty acid transport into mitochondria, supporting the high energy demands of the cardiac muscle.
Lifestyle
Regular, non-competitive exercise is recommended to maintain vascular health while avoiding extreme exertion risks.
Reducing chronic adrenaline surges helps prevent excessive strain on a heart that already struggles to relax.
Frequent echocardiograms and ECGs are essential for tracking the progression of heart wall thickening.
Maintaining adequate blood volume is critical for individuals with obstructive heart disease to ensure efficient blood flow.
Medicines
A first-in-class cardiac myosin inhibitor that restores the relaxed state of myosin and reduces outflow obstruction.
Reduce the heart rate and the force of contraction to allow the heart more time to fill with blood.
Used as an alternative to beta-blockers to improve the relaxation phase of the heart cycle.
A next-generation myosin inhibitor currently in late-stage trials for hypertrophic cardiomyopathy.
An anti-arrhythmic medication that also has a mild negative inotropic effect to help reduce obstruction.
Lab Tests & Biomarkers
Genetic Testing
The primary tool for identifying pathogenic variants in MYBPC3 and other sarcomere genes.
Evaluating family members for a specific variant found in a relative.
Clinical Markers
A marker of myocardial injury that can be chronically elevated in HCM patients.
A measure of wall stress in the heart; used to track the severity of heart failure.
Imaging & Function
Measured via echocardiogram; thickness >15mm is usually diagnostic for HCM.
An enlarged atrium is a key sign of high pressure and poor relaxation in the ventricle.
Hormonal Interactions
Thyroid Hormone (T3) Primary Regulator
Directly influences the contractile properties of the heart and the expression of sarcomere proteins.
Epinephrine Functional Activator
Drives the phosphorylation of cMyBP-C through PKA, which is essential for the "fight or flight" cardiac response.
Estrogen Protective Modulator
May help mitigate the development of heart wall thickening; men often develop more severe hypertrophy earlier.
Cortisol Stress Modulator
Chronic elevations can exacerbate the metabolic and inflammatory stress in the cardiomyopathic heart.
Growth Hormone Anabolic Activator
Influences the overall mass of the heart muscle and can contribute to hypertrophic pathways.
Aldosterone Pro-Fibrotic Hormone
High levels contribute to the buildup of scar tissue (fibrosis) in the heart muscle of HCM patients.
Deep Dive
Network Diagrams
The Molecular Brake: SRX vs. DRX States
MYBPC3-HCM Pathogenesis Flow
Biological Role: The Super-Relaxed State
The protein product, cMyBP-C, is located within the thick filament of the sarcomere. Its primary job is to regulate the “super-relaxed state” (SRX) of myosin. In this state, myosin heads are “parked” and do not consume much energy. By maintaining this balance, cMyBP-C ensures that the heart can relax efficiently between beats.
Most pathogenic mutations in MYBPC3 lead to a reduction in the total amount of functional protein, a state called haploinsufficiency. This loss of the molecular brake causes the heart muscle to become hyper-contractile and struggle to relax (diastolic dysfunction), eventually leading to the characteristic thickening of the ventricle walls.
Intervention Relevance: Targetted Myosin Inhibition
The treatment of MYBPC3-driven disease has been transformed by the arrival of cardiac myosin inhibitors. Mavacamten (Camzyos) is a first-in-class medication designed specifically for obstructive HCM. It works by inhibiting the hyper-contractile myosin heads, effectively restoring the “relaxed state” that is lost when MYBPC3 is mutated.
In addition to precision medicine, standard therapies like beta-blockers and calcium channel blockers are used to manage symptoms by slowing the heart rate. For those at high risk of arrhythmias, implantable cardioverter-defibrillators (ICDs) remain a vital safety net. Emerging research into gene therapy offers the future promise of restoring normal MYBPC3 protein levels directly in the heart cells.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The landmark study that first identified MYBPC3 as a primary genetic cause of heart muscle thickening.
Phase 3 trial results demonstrating the significant clinical benefits of direct myosin inhibition.
Comprehensive review of the molecular mechanisms of disease and emerging genetic treatments.
Mechanistic study showing how MYBPC3 mutations disrupt the metabolic "parking" of myosin heads.
Characterized the widespread founder mutation that affects millions of individuals of South Asian descent.
Identified the inflammatory signaling pathway that links sarcomere defects to cardiac scarring.